In the latest session, Ginkgo Bioworks Holdings, Inc. (DNA) saw a 1.96% increase to $8.31, outperforming the S&P 500, which had a 0.74% loss. The upcoming earnings release is anticipated to show an EPS of -$1.8 and revenue of $37 million, with yearly estimates predicting earnings of -$5.94 per share and revenue of $173 million.

The Medical – Biomedical and Genetics industry, which Ginkgo Bioworks Holdings, Inc. is a part of, currently holds a Zacks Industry Rank of 92, placing it in the top 38% of all industries. Investors should monitor analyst estimates and industry rankings for potential stock movements in the coming sessions.

Zacks is naming its Top 10 Stocks for 2026, with historical data showing significant outperformance compared to the S&P 500. Director of Research Sheraz Mian is selecting these top picks, expected to be released on January 5. Don’t miss out on the opportunity to get in early on these potential high-performing stocks.

Read more at Nasdaq: Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts